Skip to main content
Premium Trial:

Request an Annual Quote

Leerink Swann Initiates Coverage of Fluidigm

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm Leerink Swann today began coverage of Fluidigm with an "Outperform" rating and a $17 to $18 valuation.

In a research note, analyst Dan Leonard said that the addressable market for the South San Francisco, Calif.-based company, which went public last month, is poised to grow to more than $600 million from $250 million in the next three years, with growth drivers that include downstream analysis of sequencing and microarray results, single cell analysis, targeted sequencing, agriculture/livestock genotyping, and digital PCR.

"As one of the market leaders in mid-density PCR, we believe Fluidigm is well-poised to capitalize on this market growth," Leonard wrote.

The company's technology simplifies experimental workflow, increases throughput while driving down cost, and enables research that previously was "impractical," he continued. Fluidigm's microfluidics technology for mid-density genetic analysis should result in revenue growth of more than 25 percent during the next several years, and "investors will pay up for this type of growth in the small cap genomics space."

Leonard noted that the company has risks associated to its business in Japan, which accounted for 13 percent of total sales in 2009. Through the first nine months of 2010, Japan was 8 percent of total sales. Before the recent earthquake, Leonard had expected that figure to tick back up to 2009 levels going forward. Nonetheless, the "earthquake-related disruption does not alter our long-term view," Leonard said.

In early morning trading on the Nasdaq, shares of Fluidigm were down 1 percent at $15.24.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.